Clinical trial

Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review

NCT05931042

Study summary

ClinicalTrials.gov

Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Trastuzumab Normalized identity: trastuzumab View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2023-06-01

PhaseN/A

Conditions

HER2+ Breast Cancerunresolved

Interventions

TrastuzumabDRUG · verified · RxNorm: trastuzumab

Sponsors & collaborators

Rawalpindi Medical Collegelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05931042 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.